Gameto Raises $33M in Series B Financing

Gameto Raises $33M in Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On May 29, 2024, Gameto, a biotechnology company dedicated to advancing treatment options in women's health, announced the closing of an oversubscribed $33 million Series B financing round, led by Two Sigma Ventures with RA Capital and participation from existing investors, including Insight Partners, Future Ventures and BOLD Capital Partners. The financing will support the clinical development of Fertilo, Gameto’s novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body.

The WilmerHale team advising Gameto included Adam Freiman, Mark Nylen, Gabriella Stearns and Drew Fosque.

 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel